Center for Research in Security Prices, LLC

myeloMATCH uses genomics to enroll leukemia patients in targeted trials, aiming to accelerate effective treatment identification.

Simple clinical scores like NEWS outperform sophisticated AI-based models in predicting hospital patient deterioration, with eCARTv5 being the most predictive among AI tools.

Pittsburgh-based doula Alicia Vervain supports abortion patients with various methods, including singing and providing comfort measures. The rise of telehealth and medication abortions has shifted her work from clinics to homes, often involving extended support over days. This change is partly due to the COVID-19 pandemic and the 2022 U.S. Supreme Court ruling on abortion rights, which has led to more patients seeking care across state lines. Doulas like Vervain offer crucial emotional and practical support, often working for free, and are vital in managing the diverse experiences and potential complications of medication abortions.

The FAA approved SpaceX's Starship 5 launch, set for as early as Sunday, after SpaceX met all safety and environmental requirements. This fifth launch aims to catch the 21-storey booster at the launch pad using 'chopsticks,' a first-time attempt. NASA's Europa Clipper mission, also planned for Sunday, was postponed due to Hurricane Milton. Starship's IFT5 includes upgrades like a new heat shield and additional layers for better protection. SpaceX CEO Elon Musk's dispute with the FAA over a $633,000 fine and launch delays continues, with Musk threatening legal action and calling for FAA administrator Mike Whitaker's resignation.

UChicago hosts Oct. 30 event featuring scholars and leaders discussing climate and energy policy, launching a new institute addressing climate change and sustainable growth. Panels focus on U.S. and global climate policy, energy storage, clean tech, and climate systems engineering. Event includes a climate showcase, student poster session, and career fair.

Paul Stamets advocates for treating psilocybin mushrooms as nonaddictive, life-changing substances, not 'shrooms' or party drugs. Clinical trials show psilocybin can significantly improve treatment-resistant depression and other conditions. The FDA has designated psilocybin a breakthrough medicine. Psychedelics like psilocybin and LSD affect brain connectivity and neuroplasticity, offering potential benefits for various mental health issues. Microdosing, taking tiny amounts of psilocybin, is suggested for maintaining brain health, though scientific benefits are unproven. Side effects and risks exist, including potential psychosis triggers. Researchers aim to develop non-psychedelic drugs that mimic psychedelics' benefits.

Biodesix to present data on Nodify Lung® Nodule Risk Assessment use in 35,000 patients at CHEST 2024, and launch CLARIFY study to expand data package.

Government price controls on Medicare drugs, introduced by the Inflation Reduction Act, threaten healthcare innovation and patient access. Bipartisan proposals like the EPIC Act aim to mitigate these effects by standardizing exemptions for drugmakers. Clinicians should be more involved in decision-making to better navigate patient care and market dynamics.

The FDA's approval of Cobenfy (KarXT) marks a significant milestone in psychopharmacology as the first antipsychotic not targeting dopamine 2 receptors. The drug's journey began with xanomeline, synthesized by Novo Nordisk in the 1980s, showing promise in Alzheimer's and schizophrenia studies but shelved by Eli Lilly. Resurrected by Steven M. Paul, MD, who combined it with trospium at Karuna, the drug's approval highlights the industry's potential lapses in foresight and unnecessary delays in bringing effective treatments to market.